The recall of rofecoxib (Vioxx) raises the question of whether the heart attack and stroke risks uncovered in recent research are unique to this drug or common to other COX-2 inhibitors, the Oct. 9 Lancet declares in an editorial. “The short history of COX-2 inhibitors has been plagued by safety concerns,” according to the journal.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.